Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET
Company Participants
Juan Sanchez - Vice President of Corporate Communications & Investor Relations
Sharon Mates - Founder, Chairman & Chief Executive Officer
Mark Neumann - Executive Vice President & Chief Commercial Officer
Lawrence Hineline - Senior Vice President of Finance & Chief Financial Officer
Suresh Durgam - Executive Vice President & Chief Medical Officer
Conference Call Participants
Andrew Tsai - Jefferies
Jessica Fye - JPMorgan
Brian Abrahams - RBC Capital Markets
Dina Ramadane - Bank of America Securities
Charles Duncan - Cantor Fitzgerald
Marc Goodman - Leerink Partners
Michael DiFiore - Evercore ISI
Jeff Hung - Morgan Stanley
Ami Fadia - Needham & Company
Joseph Thome - TD Cowen
Graig Suvannavejh - Mizuho Securities
Joel Beatty - Baird
David Amsellem - Piper Sandler
Operator
Good morning ladies and gentlemen and welcome to Intra-Cellular Therapies Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. A slide deck that you may find helpful while you listen to this call is available on the Investor Relations Section of the Company’s website. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would like now to turn the conference over to Dr. Juan Sanchez, Vice President, Corporate Communications and Investor Relations. Sir, you may begin.
Juan Sanchez
Good morning and thank you all for joining us on our second quarter 2024 earnings call. Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Mark Neumann, Chief Commercial Officer; Dr. Suresh Durgam, Chief Medical Officer; and Larry Hineline, Chief Financial Officer.
During today's call, we will be making certain forward-looking statements. These forward-looking statements are based on current information, assumptions and expectations. Those statements are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our previous filings made with the Securities and Exchange Commission, including our quarterly and annual reports. You're cautioned not to place undue reliance on these forward-looking statements. These statements are made only as of the date of this conference call and the company disclaims any obligations to update such statements.
I will now turn the call over to Sharon.